ALFA Finder
16:18 IST
NSE
Dividend
GlaxoSmithKline Pharmaceuticals Dividend
GlaxoSmithKline Pharmaceuticals recommended a final dividend of ₹57 per equity share for 2026. The record date is May 29, 2026, pending shareholder approval.
GlaxoSmithKline Pharmaceuticals Ltd
- Share price
- ₹2,727.70
- Market cap
- ₹46,209 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 40.3×Sector 43.8×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 8Other Announcement 5Financial Results 4Annual General Meeting 4Results Update 3Management Change 3Legal & Regulatory 2Board Meeting Date 2Price Movement Clarification 1Dividend 1Business Update 1Annual Report 1
Time
35 announcements with these filters
15:50 IST
BSE
Results Update
GlaxoSmithKline Pharmaceuticals Results Update
GSK India reported full-year revenue of ₹3790 Crore and PAT of ₹1012 Crore. The board recommended a final dividend of ₹57 per equity share.
- Value
- ₹1,012 Cr
15:44 IST
BSE
Earnings Call
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK India delivered a strong FY26 with 34.3% EBITDA margins and its first-ever PAT exceeding ₹1000 cr, driven by portfolio shifts toward high-growth Specialty and Innovative segments.
14:48 IST
BSE
Financial Results
GlaxoSmithKline Pharmaceuticals Q4 FY26 Results: Net Profit ₹277.9 Cr, Up 5.7% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹995.3 Cr (+2.1% YoY) and net profit of ₹277.9 Cr (+5.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹277.9 Cr · +5.7% YoY
14:47 IST
BSE
Financial Results
GlaxoSmithKline Pharmaceuticals Financial Results
GSK Pharmaceuticals reported a consolidated net profit of ₹1,035.98 Crore for FY2026. The board also recommended a final dividend of Rs. 57 per share.
- Value
- ₹1,036 Cr